Fundz

Who to call at Arvinas, and when

Fundz watches for the moments Arvinas starts buying, and tells you who to reach.

  • An alert the day Arvinas raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Arvinas, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Arvinas. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Arvinas Enters License Agreement with Rigel Pharmaceuticals

May 12, 2026

Contract Type

licensing

New HavenBiotechnologyHealth CareTherapeuticsresearch

Description

On May 11, 2026, Arvinas, Inc. entered into a license agreement with Rigel Pharmaceuticals, Inc. This agreement grants Rigel exclusive global development, manufacturing, and commercialization rights for VEPPANU™. The collaboration aims to leverage both companies' strengths in bringing innovative treatments to market.

Quick answer

Arvinas Enters License Agreement with Rigel Pharmaceuticals (May 12, 2026). Arvinas is based in New Haven, Connecticut, United States.

What agreement did Arvinas announce on May 12, 2026?
On May 11, 2026, Arvinas, Inc. entered into a license agreement with Rigel Pharmaceuticals, Inc. This agreement grants Rigel exclusive global development, manufacturing, and commercialization rights for VEPPANU™. The collaboration aims to leverage both companies' strengths in bringing innovative treatments to market.
What does Arvinas do?
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of...
Where is Arvinas based?
Arvinas is based in New Haven, Connecticut, United States.

Source: Fundz verified event record.

Company Information

Company

Arvinas

Location

5 Science Park

New Haven, Connecticut, United States

About

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer; and vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.

Related People

Noah
Likely contact at this company
••••••••@••••••••

See Noah's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Arvinas's next move

Learn about Strategic plan

Arvinas signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.